Results 131 to 140 of about 101,598 (260)

Successful Re-administration of Granulocyte Colony-Stimulating Factor Without Recurrence of Associated Vasculitis: A Case Report. [PDF]

Cureus
Teshima K, Takahashi S, Takahashi S, Fujita N, Kume M, Takahashi N.   +5 more
europepmc   +1 more source

Reduced colony‐stimulating factor 1 receptor expression in myeloid cells has limited impact on chronic lymphocytic leukaemia progression

British Journal of Haematology, EarlyView.
Summary Targeting the colony‐stimulating factor 1 receptor (CSF1R) to remove tumour‐associated macrophages is being explored as cancer therapy. This strategy may be relevant for chronic lymphocytic leukaemia (CLL), which strongly depends on support from myeloid cells.
Natascha Rosen, Guillermo Rodriguez‐Real, Alexander F. vom Stein, Luca D. Schreurs, Trong‐Hieu Nguyen, Viktoria Kohlhas, Thanh‐Tung Truong, Maximilian Koch, Sebastian Reinartz, Sumiya Iqbal, Shaista Ilyas, Sanjay Mathur, Nina Reinart, Phuong‐Hien Nguyen, Michael Hallek   +14 more
wiley   +1 more source

Granulocyte colony-stimulating factor-induced isolated hyperbilirubinemia in acute myelogenous leukemia: A case report. [PDF]

Medicine (Baltimore)
Zrein JK, Houcheimy DA, Khalil AS.
europepmc   +1 more source

The immunological landscape of the area postrema in neuromyelitis optica spectrum disorders

Brain Pathology, EarlyView.
Aquaporin‐4 antibody‐positive neuromyelitis spectrum disorder is characterized by large tissue destructive lesions in medulla, spinal cord, and optic nerves, with only partial recovery from clinical symptoms, and by lesions with very little tissue destruction and mostly complete recovery from clinical symptoms, as seen in the area postrema ...
Qian Yu, Yoshiki Takai, Naoya Yamazaki, Sarah Brandl, Katharina M. Mair, Thibault Bouderlique, Maria Eleni Kastriti, Igor Adameyko, Romana Höftberger, Markus Reindl, Jan Bauer, Monika Bradl   +11 more
wiley   +1 more source

Long-term effects of using pegylated recombinant human granulocyte colony-stimulating factor following chemotherapy: A real-world study on patients with ovarian cancer. [PDF]

Oncol Lett
Zhang W, Tang N, Wang Y, Feng T, Yong M, Zeng Y.   +5 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Granulocyte colony-stimulating factor treatment in women with premature ovarian insufficiency: a pilot clinical study of biological activity and menstrual resumption. [PDF]

Reprod Biol Endocrinol
Sadeghi Y, Deda L, Albar M, Casper R.
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Genetic variation in targets of granulocyte colony-stimulating factor drugs and 14 cancers risk: A Mendelian randomization study. [PDF]

Medicine (Baltimore)
Zhou H, Yan S, Guo J, Yang X, Huang T.
europepmc   +1 more source

Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
The flow of this trial and the treatment schedule of adjuvant chemotherapy with nedaplatin plus docetaxel for completely resected non‐small cell lung cancer (NSCLC) (A). The primary endpoint of this study was tolerability, assessed by the completion rate of the planned four chemotherapy cycles. As a result, it was 74.3%, exceeding that reported for the
Koji Teramoto, Ryosuke Kaku, Tomoyuki Igarashi, Masayuki Hashimoto, Shoji Kitamura, Makoto Motoishi, Yuji Suzumura, Satoru Sawai, Yataro Daigo, Jun Hanaoka   +9 more
wiley   +1 more source